CODX.OQ
Latest Trade
1.06USDChange
0.00(0.00%)Volume
25,218Today's Range
-
1.1452 Week Range
-
3.77As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 1.06 |
|---|---|
Open | 1.11 |
Volume | 25,218 |
3M AVG Volume | 25.14 |
Today's High | 1.14 |
Today's Low | 1.06 |
52 Week High | 3.77 |
52 Week Low | 0.70 |
Shares Out (MIL) | 17.12 |
Market Cap (MIL) | 18.15 |
Forward P/E | -3.66 |
Dividend (Yield %) | -- |
Co-Diagnostics Inc Launches North American Mosquito Diagnostic Product
Co-Diagnostics Says All Debt Incurred In 2018 Was Eliminated In Sale Of $3 Mln Of Preferred Shares In January 2019
CVI Investments Reports A Passive Stake Of 7.8 Pct In Co-Diagnostics As Of Jan 31, 2019
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
Industry
Biotechnology & Drugs
Executive Leadership
Dwight H. Egan
Chairman of the Board, President, Chief Executive Officer
Reed L. Benson
Chief Financial Officer, Secretary
Brent Satterfield
Chief Scientific Officer
Eugene Durenard
Independent Director
Edward L. Murphy
Independent Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 212.26 |
Price To Book (MRQ) | 3.78 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -188.55 |
Return on Equity (TTM) | -172.96 |
* CO-DIAGNOSTICS, INC. ANNOUNCES CONSTRUCTION UPDATE AT JV MANUFACTURING FACILITY IN INDIA
* CO-DIAGNOSTICS INC ANNOUNCES POSITIVE RESULTS FROM CO-PRIMERS™ TECHNOLOGY IN MULTIPLEX TESTS FOR SNP DETECTION Source text for Eikon: Further company coverage:
* CO-DIAGNOSTICS - ENTERS INTO LEASE FOR BIOLOGICAL SAFETY LEVEL 2 LABORATORY FACILITY IN SALT LAKE CITY, UTAH
* Co-Diagnostics, Inc to sign purchase agreement with Medcis Pathlabs
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.